1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6A4ADEF50FBADF2958525714F005FE8A2
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/pharmaceutical-company-profiles-of-using-risk-based-approaches-in-drug-development?opendocument
18
19opendocument
2035.172.195.49
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Business Operations Manufacturing Quality Deployment

Pharmaceutical Company Profiles of Using Risk-Based Approaches in Drug Development

DB Image

ID: 4888


Features:

Graphics


Pages/Slides: 16


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

Non-members: Click here to sign-up for a complimentary tour of
"Pharmaceutical Company Profiles of Using Risk-Based Approaches in Drug Development"


Study Overview:


As the FDA transitions into using a Risk-Based Approach auditing method for inspecting the operations of pharmaceutical companies, many industry leaders are realizing the benefits of using the same model when tracking internal Quality Assurance. This research document is drawn from a larger study, Pharma R&D Quality Assurance: Staffing and Use of Risk-Based Approach Programs (#4884), commissioned to understand the effective practices of Quality Assurance at major successful pharmaceutical companies.
This larger study includes the same six slides included in these profiles on Risk-Based Approach implementation levels, but the vast majority of the study focuses on metrics for Quality Assurance areas, including GMP, GLP, GCP and validation.

These profiles are designed to give pharmaceutical managers, directors and executives an understanding of how RBA is used and whether or not their company is at par with the advanced approaches used by industry leaders and their pharmaceutical peers.

Included in this document are six blinded profiles of leading companies, drawn from a benchmark class of Abbott, Boehringer-Ingelheim, Eli Lilly, Johnson & Johnson, Novartis and Wyeth.

Key Metrics and Topic Areas:


Profiles include slides of the tools, application and impact of each companies' Risk-Based Approach implementation, along with one to two pages of details describing the following elements:

    1. Status of RBA
    2. Quality Assurance Tools Used
    3. Scoring System
    4. Risk Parameters
    5. Impact of RBA
    6. Information Sharing
    7. Perspective on ICH Guidance Q9

A portion of the Introduction to these profiles is shown below:


Industries Profiled:
Pharmaceutical; Health Care; Medical Device


Companies Profiled:
Abbott Laboratories; Boehringer-Ingelheim; Eli Lilly and Company; Novartis; Johnson & Johnson

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.